ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Kyungho Kim, Jing Li, Andrew Barazia, Alan Tseng, Seock-Won Youn, Giovanni Abbadessa, Yi Yu, Brian Schwartz, Robert K. Andrews, Victor R. Gordeuk, and Jaehyung Cho

Disclosures: Y.Y., G.A., and B.S. are employees of ArQule, Inc. Other authors declare no competing financial interests.

Contributions: K.K. and J.L. designed and performed research, collected and analyzed data, and wrote a draft of this manuscript; A.B., A.T., and S.Y. performed research; Y.Y., G.A., and B.S. provided ARQ 092 and initiated and designed research; R.K.A. provided important reagents; V.R.G. provided blood of SCD patients; and J.C. initiated and designed research, analyzed data, and wrote the manuscript.